ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,555.74
-0.16%
US Tech 100
19,107.20
-1.02%
Dow Jones
40,358.09
-0.14%
Brent Oil
80.615
-0.20%
Bitcoin
65,941.70
0.03%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Xilio Therapeutics Inc (XLO) Quote

Xilio Therapeutics Inc

Xilio Therapeutics Inc (XLO)

NASDAQ
1.01
0.021
(2.12%)
Closed July 23 4:00PM
Delayed by 15 minutes
1.03
0.02
(1.98%)
After Hours: 6:39PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
1.03
Bid
0.9501
Ask
1.05
Volume
83,262
0.9535 Day's Range 1.03
0.49 52 Week Range 2.94
Market Cap
38.02M
Previous Close
0.989
Open
0.9789
Last Trade
300
@
1.03
(formt)
Last Trade Time
Financial Volume
$ 83,714
VWAP
1.0054
Average Volume (3m)
283,680
Shares Outstanding
36,912,373
Dividend Yield
-
PE Ratio
-0.49
Earnings Per Share (EPS)
-2.07
Revenue
-
Net Profit
-76.4M

About Xilio Therapeutics Inc

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immuno... Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
xiliotx.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Xilio Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XLO. The last closing price for Xilio Therapeutics was $0.99. Over the last year, Xilio Therapeutics shares have traded in a share price range of $ 0.49 to $ 2.94.

Xilio Therapeutics currently has 36,912,373 shares outstanding. The market capitalization of Xilio Therapeutics is $36.51 million. Xilio Therapeutics has a price to earnings ratio (PE ratio) of -0.49.

XLO Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

June 17 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 17 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 17 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 13 2024
Edgar (US Regulatory)

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...

June 13 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 14 2024
Edgar (US Regulatory)

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the...

May 14 2024
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

May 07 2024
Edgar (US Regulatory)

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...

April 01 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.04034.071940992220.98971.030.91781000610.97648896CS
40.088.421052631580.951.030.861089780.94507776CS
120.021.98019801981.011.320.83662836801.04695962CS
260.386360.01242814980.64371.930.50017457171.18019652CS
52-1.81-63.73239436622.842.940.494117361.14615961CS
156-13.97-93.13333333331527.950.491950652.52694845CS
260-13.97-93.13333333331527.950.491950652.52694845CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF
 20.10
(839.25%)
128.82k
RGCRegencell Bioscience Holdings Ltd
$ 15.15
(349.55%)
1.34M
ATPCAgape ATP Corporation
$ 0.2262
(58.18%)
107.31M
SLRXSalarius Pharmaceuticals Inc
$ 2.34
(51.95%)
60.04M
GSUNGolden Sun Health Technology Group Ltd
$ 7.46
(45.42%)
589.98k
FLYEFly E Group Inc
$ 1.1601
(-81.82%)
25.44M
RNAZTransCode Therapeutics Inc
$ 0.3035
(-61.70%)
9.78M
JAGXJaguar Health Inc
$ 1.755
(-58.90%)
15.47M
MIRAMIRA Pharmaceuticals Inc
$ 2.55
(-49.10%)
25.64M
IVPInspire Veterinary Partners Inc
$ 5.19
(-43.83%)
1.67M
SLNASelina Hospitality PLC
$ 0.026
(-29.73%)
220.18M
SPWRSunPower Corporation
$ 0.9514
(32.91%)
186.75M
NVDANVIDIA Corporation
$ 122.59
(-0.77%)
173.87M
ADILAdial Pharmaceuticals Inc
$ 1.3422
(26.62%)
160.04M
HOLOMicroCloud Hologram Inc
$ 0.588
(26.07%)
135.53M

XLO Discussion

View Posts
PonkenPlonken PonkenPlonken 2 months ago
XLO -- unique masking approach and great results. Hot field $JANX. Gilead certainly thinks so - buys real equity. Company trades below the upfront payment...

https://schrts.co/tdtYZDEX
👍️0
Preciouslife1 Preciouslife1 2 months ago
Hi I tried to buy a bunch of shares this morning once at .885 then at .90; never filled though over the ASK PRICE then it took off upwards! MM MANIPULATION MUCH!?!?
👍️0
Laster Laster 3 months ago
Stock closed the gap. They are in the right biotech area similar to CLRB and CTMX and SNSE.
Only a matter of time before this explodes to $2 or higher.
JMO.
👍️0
Monksdream Monksdream 3 months ago
XLO under $2
👍️0
Laster Laster 3 months ago
The chart shows a very nice looking pennant pattern.
Biotechs are not trading well recently.
Any recovery in biotechs then this could get interesting.
Needs to move past $1.50 to confirm breakout.
Enjoy the day.
👍️0
Laster Laster 3 months ago
I remember when OCEA had similar pennant pattern before it broke out to $7.50.
Crazy times sometimes causes crazy moves.
I like the story here. Seems like a nice biotech to invest into.
JMO.
Enjoy.
👍️0
Laster Laster 3 months ago
Oops. I blinked. Missed it.
Maybe I will be quicker when it moves back to $1.20.
Unless it pops to $1.50 on no news.
Chart looks interesting. Nice pennant pattern.
Enjoy.
👍️0
Awl416 Awl416 3 months ago
Don’t blink
👍️0
Invest-in-America Invest-in-America 4 months ago
XLO: Best of luck on this one, Capt. TIm!! (I DID get both of your Post-M iHub 'emails', so I am answering both of them vis-a-vis this single one.) I am still in SHOCK that XLO did NOT soar at least 400% today.

WILD, UNPREDICTABLE, DAY TODAY!!! (And I missed all the glory behind @AVTX, to boot!! BUMMER!!!)
👍️0
TIMGZ TIMGZ 4 months ago
XLO IS MOVING , HOPEFULLY THE TORTOISE-LIKE CONTINUES*****
IN THE NEXT 3 HOURS AND PR MONDAY SHOULD BE MORE GLORIOUS****WE SHALL SEE***


THAT WAS AN EXCELLENT PR BUT THE PLAN ALL ALONG WAS SNAKE-OIL-LIKE
👍️0
Invest-in-America Invest-in-America 4 months ago
XLO: Worthless piece of SHIT!!!
👍️0
Invest-in-America Invest-in-America 4 months ago
XLO: Oooooooo, Boy!!! (Latest 'Chart', below, looks pretty good!!!)




"I gots my entire weekly ALLOWANCE in this, sucka!!! So you BETTER gets to Planet Jupiter pretty damn QUICK!!!"
👍️0
Invest-in-America Invest-in-America 4 months ago
XLO: Halted.
👍️0
JPetroInc JPetroInc 4 months ago
nice news on XLO

looks a lot like iBio news

good fortunes to all XLO shareholders …

EOM
💩 1 🤡 1
Awl416 Awl416 4 months ago
Watch out for these dirty algo’s
👍️0
Awl416 Awl416 4 months ago
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
👍️0
Awl416 Awl416 4 months ago
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
👍️0
crudeoil24 crudeoil24 2 years ago
Price target > 36.00 > HC Wainwright & Co. analyst Michael King initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Buy rating and announces Price Target of $36.

Latest Ratings for XLO DateFirmActionFromTo

Jan 2022HC Wainwright & Co.Initiates Coverage OnBuy Nov 2021Raymond JamesInitiates Coverage OnOutperform Nov 2021Cowen & Co.Initiates Coverage OnOutperform

👍️0
crudeoil24 crudeoil24 2 years ago
TODAY > Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Rene Russo, Pharm. D., president and chief executive officer, and Marty Huber, M.D., president of research and development and chief medical officer of Xilio Therapeutics, will participate in a virtual fireside chat during the Guggenheim 4 Annual Oncology Day on Thursday, February 10, 2022, at 8:30 a.m. ET.

A live webcast will be available in the Investors and Media section of the Xilio Therapeutics' website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.
👍️0
crudeoil24 crudeoil24 2 years ago
Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity
👍️0

Your Recent History

NASDAQ
XLO
Xilio Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved